Robotic Workstation Prints 2.4 Million Microarrays per Year
By LabMedica International staff writers Posted on 31 Dec 2009 |
Advance in the speed and efficiency of manufacturing microarrays allows highly precise printing of as many as 2.4 million microarrays per year with a single robotic workstation. The microarrays are tiny glass substrates that contain rows and columns of printed spots used for molecular diagnostics and scientific research.
The technological breakthrough was made by Arrayit Corporation (Sunnyvale, CA, USA); its current capacity is 640,000 microarrays per instrument annually. The enhanced automated microarray printing bandwidth increases company's competitiveness in the diagnostics marketplace.
Arrayit executive vice president and cofounder Todd Martinsky stated, "This technological advance represents an engineering tour de force that combines our expertise in laboratory automation, linear drive robotics, micromachining, surface chemistry and contact printing. Leveraging our core tech competencies and patented contact printing platform in this manner should further enhance our competitive differentiation in the diagnostics market."
Arrayit Corporation discovers, develops, and manufactures life science technologies and consumables for disease prevention, treatment, and cure. The company is currently developing early stage definitive diagnostic tests for ovarian cancer, Parkinson's disease, influenza A virus (H1N1) and other illnesses.
Related Links:
Arrayit Corporation
The technological breakthrough was made by Arrayit Corporation (Sunnyvale, CA, USA); its current capacity is 640,000 microarrays per instrument annually. The enhanced automated microarray printing bandwidth increases company's competitiveness in the diagnostics marketplace.
Arrayit executive vice president and cofounder Todd Martinsky stated, "This technological advance represents an engineering tour de force that combines our expertise in laboratory automation, linear drive robotics, micromachining, surface chemistry and contact printing. Leveraging our core tech competencies and patented contact printing platform in this manner should further enhance our competitive differentiation in the diagnostics market."
Arrayit Corporation discovers, develops, and manufactures life science technologies and consumables for disease prevention, treatment, and cure. The company is currently developing early stage definitive diagnostic tests for ovarian cancer, Parkinson's disease, influenza A virus (H1N1) and other illnesses.
Related Links:
Arrayit Corporation
Latest Molecular Diagnostics News
- Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
- First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
- Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
- AI Technology-Based Blood Test Identifies Lung Cancer Earlier
- Ultra-Sensitive Blood Test Predicts Breast Cancer Recurrence Months or Even Years before Relapse
- Prenatal Testing Offers Window for Finding Mother’s Cancer Risk
- New Molecular Test Detects More Cervical Cancer Cases
- New Panel Quickly and Accurately Identifies 16 Common Gastrointestinal Pathogens
- New DNA Testing Method Offers Faster and More Accurate Pathogen Identification
- Precise Cancer Detection Method as Quick and Easy as Blood Test
- DNA Spit Test More Accurate At Identifying Future Prostate Cancer Risk
- Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
- Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
- New Assay Detects Heart Failure Biomarker in Less than 11 Minutes
- Innovative Test Improves Assessment of Patients with Mild Traumatic Brain Injury
- New Method for Lung Microbiomes Analysis Predicts Mortality in Children after Bone Marrow Transplant